Buchumschlag

He shoots, he scores: Navigating the complex world of transcriptomic scores in the age of artificial intelligence

Fuente: Wiley Open Access

Gespeichert in:

Bibliographische Detailangaben
1. Verfasser:	David G. Kent
Format:	Artículo Open Access
Veröffentlicht:	Wiley 2024
Schlagworte:	HemaSphere
Online-Zugang:	Acceder al recurso
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge

New approaches in gene therapy for sickle cell disease, moving in vivo
von: David G. Kent
Veröffentlicht: (2024)

Waiting and seeing: The importance of long‐term system‐wide monitoring of mouse models of disease
von: David G. Kent
Veröffentlicht: (2025)

HLA evolutionary divergence score after donor lymphocyte infusion following allogeneic hematopoietic stem cell transplantation
von: Sophie Le Grand, et al.
Veröffentlicht: (2025)

Prognostic value of flow cytometry in myelodysplastic neoplasms (MDS): Composition of a FCM‐prognostic score (FCM‐PS) for overall survival
von: Aida Santaolalla, et al.
Veröffentlicht: (2026)

Integrating transcriptomic profiling and machine learning: A clinically actionable prognostic model for infant acute myeloid leukemia
von: Yu Tao, et al.
Veröffentlicht: (2025)

Fetal‐hemoglobin‐expressing red blood cells (“F cells”) consist of three distinct types as revealed by single‐cell transcriptomic analysis of circulating reticulocytes
von: Helen Rooks, et al.
Veröffentlicht: (2025)

Navigating the evolving management of smoldering multiple myeloma
von: M. Bakri Hammami, et al.
Veröffentlicht: (2026)

Brexucabtagene autoleucel for relapsed or refractory mantle cell lymphoma in the United Kingdom: A real‐world intention‐to‐treat analysis
von: Maeve A. O'Reilly, et al.
Veröffentlicht: (2024)

Eligibility criteria for clinical trials in AL amyloidosis result in exclusion of nearly half of real‐world patients
von: Claudia Bellofiore, et al.
Veröffentlicht: (2026)

Cytopenic overt primary myelofibrosis at presentation: Analysis of outcomes in the prospective, real‐world ERNEST‐2 registry
von: Paola Guglielmelli, et al.
Veröffentlicht: (2025)

Elevated circulating tumor cells reflect high proliferation and genomic complexity in multiple myeloma
von: Juan‐Jose Garces, et al.
Veröffentlicht: (2025)

Prospective genetic germline evaluation in a consecutive group of adult patients aged <60 years with myelodysplastic syndromes
von: Enrico Attardi, et al.
Veröffentlicht: (2024)

NK‐type large granular lymphocyte leukemia comes of age
von: Gianpietro Semenzato, et al.
Veröffentlicht: (2025)

3D Tumor microenvironment interaction reveals AP‐1 complex regulation and contact‐mediated reprogramming of bone marrow stromal cells in chronic lymphocytic leukemia
von: Jana Lindacher, et al.
Veröffentlicht: (2025)

Evaluation of the R2‐ISS in real‐world patients with newly diagnosed multiple myeloma: A nationwide cohort study by the Korean Multiple Myeloma Working Party (KMM 2202)
von: Hyungwoo Cho, et al.
Veröffentlicht: (2024)

Fitness beyond age: Multidisciplinary expert opinion on redefining fitness for targeted therapies in chronic lymphocytic leukemia
von: Raúl Córdoba, et al.
Veröffentlicht: (2026)

CD49d expression is included in a revised 4‐factor model predicting outcome in patients with chronic lymphocytic leukemia treated with ibrutinib: A multicenter real‐world experience
von: Riccardo Bomben, et al.
Veröffentlicht: (2024)

Biological heterogeneity in adult IRF4 ‐rearranged large B‐cell lymphoma: Stratification by age and anatomical site
von: Yuxiu Zhang, et al.
Veröffentlicht: (2026)

Intra‐subtype heterogeneity shapes treatment response in KMT2A ‐rearranged ALL across all age groups
von: Alina M. Hartmann, et al.
Veröffentlicht: (2026)

First‐line ibrutinib treatment in patients with chronic lymphocytic leukemia is associated with overall survival rates similar to those of an age‐matched general population: A pooled post hoc analysis
von: Paolo Ghia, et al.
Veröffentlicht: (2024)

Chimeric antigen receptor‐T cell therapy shows similar efficacy and toxicity in patients with diffuse large B‐cell lymphoma aged 70 and older compared to younger patients: A multicenter cohort study
von: Philipp Berning, et al.
Veröffentlicht: (2024)

Imlifidase for hematologists: Creating a therapeutic window in the presence of neutralizing alloantibodies
von: Roger E. G. Schutgens
Veröffentlicht: (2024)

Causes of death among patients diagnosed with chronic lymphocytic leukemia: A population‐based study in the Netherlands, 1996–2020
von: Lina van der Straten, et al.
Veröffentlicht: (2024)

Models for the marrow: A comprehensive review of AI‐based cell classification methods and malignancy detection in bone marrow aspirate smears
von: Tabita Ghete, et al.
Veröffentlicht: (2024)

Mild or moderate hemophilia is not always a mild or moderate bleeding disorder: Back to the clinical phenotype
von: Francesco Rodeghiero, et al.
Veröffentlicht: (2025)

Extracellular vesicles from chronic lymphocytic leukemia cells promote leukemia aggressiveness by inducing the differentiation of monocytes into nurse‐like cells via an RNA‐dependent mechanism
von: Nathan Dubois, et al.
Veröffentlicht: (2025)

Response to luspatercept can be predicted and improves overall survival in the real‐life treatment of LR‐MDS
von: Angela Consagra, et al.
Veröffentlicht: (2025)

Early peripheral blood and bone marrow MRD as prognostic markers in quadruplet‐treated multiple myeloma without transplant
von: Benjamin A. Derman, et al.
Veröffentlicht: (2025)

Transcriptional profiling directs the classification of acute leukemias of ambiguous lineage into AML, B‐ALL, or T‐ALL
von: Roger Mulet‐Lazaro, et al.
Veröffentlicht: (2025)

Treatment patterns and outcomes with luspatercept in patients with lower‐risk myelodysplastic syndromes: A retrospective US cohort analysis
von: Sudipto Mukherjee, et al.
Veröffentlicht: (2024)

NOTCH1 fusions in pediatric T‐cell lymphoblastic lymphoma: A high‐risk subgroup with CCL17 (TARC) levels as diagnostic biomarker
von: Emma Kroeze, et al.
Veröffentlicht: (2024)

Dynamics of complete responses (CRs) in patients with relapsed or refractory follicular lymphoma (R/R FL) treated with odronextamab in the ELM‐2 study
von: Stefano Luminari, et al.
Veröffentlicht: (2026)

Risk of central nervous system versus systemic relapse in patients with diffuse large B‐cell lymphoma treated with R‐CHOP: What should we focus on?
von: Magdalena Klanova, et al.
Veröffentlicht: (2025)

Assessing frailty in myeloma: The pursuit of simplicity may sacrifice precision of predicting clinical outcomes
von: Kazimierz Groen, et al.
Veröffentlicht: (2024)

Uncovering the ultra‐frail: A distinct subgroup in non‐transplant eligible newly diagnosed patients with multiple myeloma, with an inferior clinical outcome
von: Kazimierz Groen, et al.
Veröffentlicht: (2025)

CHIC: A machine learning framework for inferring the presence of high‐risk clonal hematopoiesis using complete blood count data from 431,531 UK Biobank participants
von: William G. Dunn, et al.
Veröffentlicht: (2025)

Outcomes of tafasitamab and lenalidomide in large B‐cell lymphoma based on prior CD19‐directed CAR T exposure
von: Mwanasha H. Merrill, et al.
Veröffentlicht: (2025)

Circulating tumor plasma cells and peripheral blood measurable residual disease assessment in multiple myeloma patients not planned for upfront transplant
von: Prashant R. Tembhare, et al.
Veröffentlicht: (2024)

Prognostic relevance of molecular measurable residual disease detection in AML with mutated CEBPA
von: Christian M. Vonk, et al.
Veröffentlicht: (2024)

Immune‐monitoring of myelodysplastic neoplasms: Recommendations from the i4MDS consortium
von: Cristina A. Tentori, et al.
Veröffentlicht: (2024)